Recombinant IgM Antibody Production Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing IgM antibodies with specificity for gangliosides, such as GD3, GD2, and GM3, are inefficient for industrial-scale manufacture and have limited therapeutic and diagnostic applications due to low expression titers and instability in hybridoma systems, which restricts their use in cancer therapy.
Innovation Solution
A recombinant human IgM monoclonal antibody is expressed in CHO cells using optimized gene constructs and transfection techniques, resulting in high-titer, stable production of the pentameric IgM/GD3 antibody that specifically binds to GD3, GM3, GM1, and GD2 gangliosides, enabling effective targeting of malignant tumor cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hybridoma systems are used to produce IgM antibodies against gangliosides, then antibody production is achieved, but expression titers are low and stability is poor
Solution Approach 1:
The patent changes the production system from hybridoma to recombinant expression in CHO cells, altering the fundamental parameters of cell line, expression vector, and culture conditions to achieve both high stability and high expression titers of IgM antibodies
Solution Approach 2:
The patent replaces the biological hybridoma system with a recombinant DNA-based expression system, substituting one biological mechanism with another that offers improved control, stability, and productivity for IgM antibody production
2Manufacturing precision
If conventional IgM antibody production methods are used, then antibody specificity for gangliosides is achieved, but industrial-scale manufacture is inefficient
Solution Approach 1:
The patent optimizes multiple parameters including cell line (CHO), expression vector design, transfection methods, and culture conditions to simultaneously achieve high antibody specificity for gangliosides and efficient industrial-scale production
Solution Approach 2:
The patent creates a universal recombinant expression platform that can produce IgM antibodies with specific binding to multiple gangliosides (GD3, GM3, GD2, GM1) while maintaining high manufacturing efficiency and scalability
3Productivity
If IgM antibodies are produced with high expression levels, then therapeutic potential is enhanced, but production stability is compromised in hybridoma systems
Solution Approach 1:
The patent uses immortalized CHO cell lines that can be continuously cultured and produce high levels of IgM antibodies without the instability and limited lifespan inherent in hybridoma systems, enabling sustained high-level production
Solution Approach 2:
The patent implements controlled expression systems with selectable markers and optimized culture conditions that provide feedback mechanisms to maintain stable high-level IgM antibody production in CHO cells over extended periods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant IgM/GD3 antibody achieves significantly higher expression levels and stability, allowing for industrial-scale production and efficient binding to multiple gangliosides, demonstrating enhanced therapeutic potential against various cancers with minimal non-specific binding to normal cells.
Implementation Method 1
The IgM antibody is capable of recognizing different purified ganglioside antigens and that is also capable of specifically binding and killing different malignant tumour or cancer cells
Implementation Method 2
specifically binding and killing different malignant tumour or cancer cells via activation of complement effector function
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to a recombinant human monoclonal pentameric IgMantibody comprising the following characteristics: capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, estrogen receptor-negative metastatic breast cancer cells. The invention further relates to a cell line producing the IgM antibody and to the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.